These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 23690480)

  • 1. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
    Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
    J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
    Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
    Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
    Palazón A; Teijeira A; Martínez-Forero I; Hervás-Stubbs S; Roncal C; Peñuelas I; Dubrot J; Morales-Kastresana A; Pérez-Gracia JL; Ochoa MC; Ochoa-Callejero L; Martínez A; Luque A; Dinchuk J; Rouzaut A; Jure-Kunkel M; Melero I
    Cancer Res; 2011 Feb; 71(3):801-11. PubMed ID: 21266358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B.
    Jang IK; Lee ZH; Kim YJ; Kim SH; Kwon BS
    Biochem Biophys Res Commun; 1998 Jan; 242(3):613-20. PubMed ID: 9464265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.
    Melero I; Murillo O; Dubrot J; Hervás-Stubbs S; Perez-Gracia JL
    Trends Pharmacol Sci; 2008 Aug; 29(8):383-90. PubMed ID: 18599129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
    Sica G; Chen L
    Arch Immunol Ther Exp (Warsz); 1999; 47(5):275-9. PubMed ID: 10604232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
    Shi W; Siemann DW
    Anticancer Res; 2006; 26(5A):3445-53. PubMed ID: 17094465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy.
    Snell LM; Lin GH; McPherson AJ; Moraes TJ; Watts TH
    Immunol Rev; 2011 Nov; 244(1):197-217. PubMed ID: 22017440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death.
    Zhang B; Zhang Y; Niu L; Vella AT; Mittler RS
    J Immunol; 2010 May; 184(9):4770-8. PubMed ID: 20351189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.
    Martínez Gómez JM; Koh VH; Yan B; Lin W; Ang ML; Rahim SZ; Pethe K; Schwarz H; Alonso S
    Immunobiology; 2014 Jan; 219(1):78-86. PubMed ID: 24091276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
    Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
    Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.
    Zapata JM; Perez-Chacon G; Carr-Baena P; Martinez-Forero I; Azpilikueta A; Otano I; Melero I
    Front Immunol; 2018; 9():2618. PubMed ID: 30524423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.
    May KF; Chen L; Zheng P; Liu Y
    Cancer Res; 2002 Jun; 62(12):3459-65. PubMed ID: 12067989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.